2029, Diabetes and Labelling - Pharmacist Digest

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2029

Diabetes

Labelling

Novo Nordisk blockbuster Ozempic boasts 23% sales surge in 2023

Pharmaceutical Technology

APRIL 28, 2023

Originally granted approval in its largest market, the US, in 2017, Ozempic has subsequently obtained approval for three distinct dosages, 0.5mg, 1.0mg, and 2.0mg, for the treatment of type 2 diabetes. It is forecast that Ozempic will sustain its sales growth over the next five years, with an expected annual sales figure of $17bn in 2029.

Diabetes

Diabetes Dosage Labelling Compounding

T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Novo Nordisk blockbuster Ozempic boasts 23% sales surge in 2023

T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies

Stay Connected